Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab versus placebo in adults with primary Sjogren's syndrome
NL-OMON52271Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of nipocalimab in Sjögren's syndrome (SS), sponsored by Janssen Pharmaceutical. Planned start Oct 2021; status: withdrawn.
02
Drugs
nipocalimab
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on NL-OMON52271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52271.